Skip to main content Skip to search Skip to main navigation

PAT CONNECT 2026: Register now!

The PAT Connect Conference will take place in Badenweiler on March 10 and 11, 2026. It brings together experts in pharmaceutical process analytics from industry, science, and regulatory authorities. 

Expand your network. 

Program and registration

On March 12, you will have the opportunity to visit the Glatt Innovation Center in Weil-Haltingen.

The international conference expects 150 to 250 leading experts from industry, science, and government agencies to discuss the latest developments in process analytical technology (PAT). Special focus will be placed on AI applications, continuous production, and data analytics, supplemented by regulatory perspectives and practical examples from industry.

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What are the Prospects and Developments in the Operation of Computerised Systems?

What are the Prospects and Developments in the Operation of Computerised Systems?

Here's the answer:
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Switzerland: Updated MRA with the EU to Ease Market Access of Medical Devices

Switzerland: Updated MRA with the EU to Ease Market Access of Medical Devices

MedTech Europe and partner associations welcomed the EU–Switzerland agreement package, including the long-awaited update of the Mutual Recognition Agreement (MRA).
Read more
FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Previous
Next